Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693291 | 0.91 | THRB (0.38) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL6692377 | 0.87 | LMNA (0.58) | SMN1; SMN2LMNAHPGDHTTNPSR1 | |
| SCHEMBL6692440 | 0.81 | THRB (0.36) | SMN1; SMN2LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL6689854 | 0.80 | L3MBTL1 (0.39) | SMN1; SMN2LMNAL3MBTL1HTTMEN1 | |
| SCHEMBL6689993 | 0.80 | RORC (0.48) | — | |
| SCHEMBL6697630 | 0.79 | LMNA (0.55) | SMN1; SMN2LMNAHPGDHTTNPSR1 | |
| SCHEMBL6690029 | 0.73 | THRB (0.43) | — | |
| SCHEMBL6694254 | 0.73 | CA12 (0.34) | LMNAHTTMEN1KMT2AALDH1A1 | |
| SCHEMBL6694244 | 0.72 | THRB (0.41) | SMN1; SMN2LMNAHPGDL3MBTL1NPSR1 | |
| SCHEMBL6694174 | 0.72 | THRB (0.45) | SMN1; SMN2LMNAKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | SMN1; SMN2 3943/4885LMNA 4794/4885HPGD 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.